Full-Time

Associate Director

Risk Based Quality Management Operations

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term and/or long-term incentives + 401(k) company match

Massachusetts, USA

Remote

Category
Biology & Biotech (1)
Required Skills
Risk Management
Data Analysis

Get referred to Takeda

See people who can refer or advise you

Requirements
  • The candidate must have 8 or more years of experience in the pharmaceutical or contract research organization industry.
  • The candidate must have 3 or more years of experience in Risk Based Quality Management.
  • The candidate must have 2 or more years of managerial and supervisory experience.
  • The candidate must have a robust understanding of the drug development process and clinical trial execution.
  • The candidate must know industry regulatory standards including 21 CFR Part 11, ICH E6, and ICH E8 (Good Clinical Practice).
  • The candidate must have experience in risk management, sponsor audits and health authority inspections, root cause analyses, mitigation strategies, and Corrective Actions Preventive Actions.
  • The candidate must know Risk Based Quality Management information technology systems or other data analytic systems.
  • The candidate must be able to analyze data, identify patterns, and make recommendations for improvement.
  • The candidate must be able to effectively lead cross-functional team meetings.
  • The candidate must have experience forming cross-functional collaborations.
  • The candidate must be able to influence without authority.
  • The candidate must be able to prioritize and take decisive action.
  • The candidate must be comfortable with ambiguity.
  • The candidate must have excellent teamwork, organizational, interpersonal, and problem-solving skills.
  • The candidate must demonstrate assertive and collaborative communication.
  • The candidate must have an aptitude for data analytics and an analytical mindset.
  • The candidate must have attention to detail and be a critical thinker.
  • The candidate must demonstrate a diversity and inclusion mindset and set an example for these behaviors.
  • The candidate must be able to communicate effectively across functions with people at various levels.
Responsibilities
  • The role supports development of Risk Based Quality Management processes at the program, portfolio, and asset levels, ensuring risks and issues are cascaded to studies and escalated to program level when they may impact broader outcomes.
  • The role contributes to creating a lessons learned framework so insights from Risk Based Quality Management activities are captured and applied to future studies with similar characteristics.
  • The role may represent Risk Based Quality Management Operations at the Global Program Team level for priority assets, providing strategic input and risk oversight.
  • The role assists Directors with departmental responsibilities, including study tracking and resource allocation planning.
  • The role may support quality control activities for other Risk Based Quality Management Operational Leads, including Trial Master File filing, study risk assessments, and centralized monitoring actions.
  • The role contributes to developing and interpreting program-level reports and extracting insights that inform and enhance Risk Based Quality Management processes across studies.
  • The role supports process design and adoption of the risk assessment tool.
  • The role may implement Risk Based Quality Management procedures for assigned studies, including study risk assessment and centralized monitoring.
  • The role identifies and shares best practices, successes, case studies, failures, and process improvement opportunities to promote continuous improvement and consistency with Risk Based Quality Management processes.
  • The role acts as a change agent, champion, subject matter expert, and point of contact for Risk Based Quality Management methodology, leading study teams to understand and follow best practices.
  • The role supports inspections and regulatory interactions related to Takeda’s adoption of the Risk Based Quality Management framework.
  • The role may perform line management of other junior staff within Risk Based Quality Management Operations.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.